Cargando…

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer

BACKGROUND: Immunotherapies targeting programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have been approved for gastric cancer (GC) patients. However, a large proportion of patients with T-cell-inflamed tumor microenvironment do not respond to the PD-1/PD-L1 blockade. The stromal c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Qianqian, Zhu, Peng, Zhang, Hui, Ye, Tianhe, Liu, Dehan, Gong, Zhao, Xia, Xiangwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092673/ https://www.ncbi.nlm.nih.gov/pubmed/32226313 http://dx.doi.org/10.1186/s12935-020-01173-3

Ejemplares similares

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
por: Jiang, Cui, et al.
Publicado: (2019)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Huang, Zi-Lu, et al.
Publicado: (2019)

miR-502-5p affects gastric cancer progression by targeting PD-L1
por: You, Wendao, et al.
Publicado: (2020)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma
por: Gao, Qian, et al.
Publicado: (2021)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy
por: Wu, Xiangyan, et al.
Publicado: (2022)

Analysis of PD-1 related immune transcriptional profile in different cancer types
por: Shang, Jun, et al.
Publicado: (2018)

Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
por: Zhang, Ao, et al.
Publicado: (2021)

Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer
por: Han, Yanyan, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
por: Boldrini, Laura, et al.
Publicado: (2017)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer
por: Gu, Xiaobin, et al.
Publicado: (2019)

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
por: Li, Kang, et al.
Publicado: (2022)

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
por: Gao, Zheng, et al.
Publicado: (2022)

A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
por: Yang, Jing, et al.
Publicado: (2020)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
por: Liu, Gao-Min, et al.
Publicado: (2019)

Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
por: Jiang, Xiufeng, et al.
Publicado: (2019)

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients
por: Deng, Min, et al.
Publicado: (2021)

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC
por: Zhang, Qiao, et al.
Publicado: (2020)

Stromal-epithelial responses to fractionated radiotherapy in a breast cancer microenvironment
por: Qayyum, Muqeem A., et al.
Publicado: (2015)

Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling
por: Li, Zhi, et al.
Publicado: (2020)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ohacom8smmm2dn7jigg6fcjjdu